Oaktree Acquisition Corp. III Reports Q3 2025 Net Income of $1.97M, Seeks Acquisition Opportunities

Oaktree Acquisition Corp. III Life Sciences reported its financial results for the third quarter of 2025, revealing a net income of $1,966,742 for the three months ending September 30, 2025, compared to a net loss of $48,095 during the same period in 2024. The company generated $2,192,321 in interest income from cash held in its trust account, which significantly contributed to its profitability. For the nine months ended September 30, 2025, the net income totaled $5,499,876, driven by interest earnings of $6,440,067, while general and administrative expenses amounted to $940,191.

The company’s total assets increased to $201,249,963 as of September 30, 2025, up from $195,250,622 at the end of 2024. This growth was primarily attributed to an increase in cash held in the trust account, which rose to $199,769,089 from $193,579,022. However, the company also reported a rise in current liabilities, which increased to $1,226,788 from $727,323, largely due to an obligation to a related party amounting to $710,857.

In terms of operational developments, Oaktree Acquisition Corp. III has not yet identified a specific target for its initial business combination, as it remains in the process of searching for suitable acquisition opportunities. The company has maintained its focus on utilizing the proceeds from its initial public offering (IPO) and private placements to fund its acquisition plans. As of September 30, 2025, the company had 19,199,029 Class A ordinary shares subject to possible redemption, reflecting its ongoing commitment to providing liquidity options for shareholders.

Strategically, the company has made key organizational changes, including the appointment of David A. Berry, MD, PhD, as an independent director on October 17, 2025, and the resignation of Chief Financial Officer Thomas Sweeney, effective October 29, 2025, with George A. Martinez appointed as his successor. These changes are part of the company's efforts to strengthen its governance and oversight as it prepares for future business combinations.

Looking ahead, Oaktree Acquisition Corp. III has until October 25, 2026, to complete its initial business combination. The company acknowledges the potential challenges it may face in raising additional capital and the risks associated with market conditions and geopolitical events. Management has indicated that if a business combination is not consummated by the deadline, the company may seek to extend the combination period, subject to shareholder approval. The company’s ability to continue as a going concern remains uncertain, contingent on its success in securing additional financing and completing a business combination.